|
|
| (One intermediate revision by the same user not shown) |
| Line 7: |
Line 7: |
| IDE could help creating IDE-based therapies to control cerebral Aβ and blood sugar concentrations thanks to the understanding of its molecular mechanisms. | | IDE could help creating IDE-based therapies to control cerebral Aβ and blood sugar concentrations thanks to the understanding of its molecular mechanisms. |
| IDE is an unusual enzyme because of its high affinity for substrates that are widely diverse in sequence and structure. IDE prefers to degrade <6 kDa bioactive peptides such as insulin, Aβ, glucagon, atrial natriuretic peptides or transforming growth factor α. Paradoxally, even though IDE targets a broad range of substrates, it shows a remarkable capacity to selectively cleave some peptides without degrading related family members. | | IDE is an unusual enzyme because of its high affinity for substrates that are widely diverse in sequence and structure. IDE prefers to degrade <6 kDa bioactive peptides such as insulin, Aβ, glucagon, atrial natriuretic peptides or transforming growth factor α. Paradoxally, even though IDE targets a broad range of substrates, it shows a remarkable capacity to selectively cleave some peptides without degrading related family members. |
| | |
| | See [[Human Insulin Degrading Enzyme (Hebrew)]]. |
|
| |
|
| == How are the structure and the functions of IDE related? == | | == How are the structure and the functions of IDE related? == |
| Line 50: |
Line 52: |
| </StructureSection> | | </StructureSection> |
| __NOTOC__ | | __NOTOC__ |
|
| |
| ==3D structures of insulin-degrading enzyme==
| |
|
| |
| Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
| |
| {{#tree:id=OrganizedByTopic|openlevels=0|
| |
|
| |
| *Insulin-degrading enzyme
| |
|
| |
| **[[2jg4]] - hIDE (mutant) – human<br />
| |
| **[[3qz2]] - hIDE<br />
| |
| **[[6bf6]], [[6b7y]] – hIDE – Cryo EM<br />
| |
| **[[3p7l]] - rIDE – rat<br />
| |
|
| |
| *Insulin-degrading enzyme binary complexes
| |
|
| |
| **[[3n56]], [[3n57]] – hIDE (mutant) + B-type natriuretic peptide <br />
| |
| **[[3ofi]] - hIDE + ubiquitin<br />
| |
| **[[3h44]] - hIDE (mutant) + C-C motif chemokine 3<br />
| |
| **[[4ral]] - hIDE (mutant) + C-C motif chemokine 4<br />
| |
| **[[3hgz]], [[2g48]] - hIDE (mutant) + amylin<br />
| |
| **[[3e4z]] - hIDE (mutant) + insulin-like growth factor II<br />
| |
| **[[3e50]] - hIDE (mutant) + Transforming growth factor α<br />
| |
| **[[3e4a]] – hIDE (mutant) + hydroxamate peptide II1<br />
| |
| **[[2wby]], [[2wc0]] - hIDE (mutant) + insulin<br />
| |
| **[[3cww]] - hIDE (mutant) + Bradykinin N terminal peptide<br />
| |
| **[[2jbu]] - hIDE (mutant) + co-purified peptide<br />
| |
| **[[2g47]], [[2wk3]] - hIDE (mutant) + amyloid β A4 residues 1-40<br />
| |
| **[[2g49]] - hIDE (mutant) + glucagons<br />
| |
| **[[2g56]] - hIDE + insulin β chain <br />
| |
| **[[4dtt]], [[4dwk]], [[4nxo]], [[4qia]] – hIDE + inhibitor<br />
| |
| **[[4gs8]], [[4gsc]], [[4gsf]], [[4ifh]], [[2ypu]], [[4lte]], [[4pf7]], [[4pf9]], [[4pfc]], [[4re9]], [[6mq3]] - hIDE (mutant) + inhibitor<br />
| |
| **[[3p7o]] - rIDE (mutant) + peptide<br />
| |
| **[[4iof]] – hIDE + antibody<br />
| |
| **[[5uoe]] – hIDE (mutant) + antibody <br />
| |
| **[[6bf7]], [[6bf9]], [[6b7z]] – hIDE + antibody – Cryo EM<br />
| |
| **[[6bf8]], [[6bfc]], [[6b3q]] – hIDE + insulin – Cryo EM<br />
| |
|
| |
| *Insulin-degrading enzyme ternary complexes
| |
|
| |
| **[[4m1c]] – hIDE + antibody + amyloid β A4 protein residues 1-40<br />
| |
| **[[6eds]] - hIDE (mutant) + glucagon + inhibitor<br />
| |
| **[[2g54]] - hIDE (mutant) + insulin chain + Zn<br />
| |
| **[[4pes]], [[6byz]] - hIDE (mutant) + inhibitor + tripeptide<br />
| |
| **[[6b70]] – hIDE + antibody + insulin – Cryo EM<br />
| |
| **[[4q5z]] – hIDE + antibody + insulin<br />
| |
| **[[5cjo]] – hIDE (mutant) + antibody + insulin<br />
| |
| **[[3tuv]] - rIDE + peptide + ATP
| |
|
| |
| }}
| |
|
| |
|
| == References == | | == References == |